USA
Outside the US
Healthcare
Professionals Patients
Customer Portal
Logo
Menu
USA
Customer Portal
Outside the US

Now available
for DLBCL

The first Medicare-reimbursed MRD
assay for patients with DLBCL,
available as a CLIA-validated LDT.

$0 cost for Medicare patients—and with
no frequency restrictions.

LEARN MORE

ADAPTIVE ASSISTTM

We do the work:
Adaptive Assist ensures no patient is left behind

Adaptive Assist FAQs for clinicians

English
ESPAÑOL

How we support patients:

Upfront, out-of-pocket, and Good Faith Estimates

Prior authorization management

Appeal denials on the patient’s behalf

Assistance with out-of-pocket costs for qualifying patients

Good Faith Estimates for patients

Patient testing is never held due to coverage concerns

5-minute enrollment

Rapid verification

Call our Patient Support Team at
1 (855) 236-9230

Download the Adaptive Assist Application Form for your patients

English
Español

This page is intended for a US-based audience.

clonoSEQ® is available as an FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect minimal residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). CLL Clonality (ID) Tests will also produce an IGHV status result, which is provided as a CLIA-validated laboratory developed test (LDT) but which has not been cleared or approved by the FDA. Additionally, clonoSEQ is available for use in other lymphoid cancers and specimen types as a CLIA-validated LDT. For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit clonoSEQ.com/technical-summary.